This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Buchner T, Krug UO, Gale RP, Heinecke A, Sauerland C, Haferlach C et al. Age, not therapy-intensity, determines outcomes of adults with acute myeloid leukaemia. Leukemia 2016.
Burnett AK, Russell NH, Hills RK, Hunter AE, Kjeldsen L, Yin J et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol 2013; 31: 3360–3368.
Plunkett W, Liliemark JO, Adams TM, Nowak B, Estey E, Kantarjian H et al. Saturation of 1-beta-D-arabinofuranosylcytosine 5’-triphosphate accumulation in leukemia cells during high-dose 1-beta-D-arabinofuranosylcytosine therapy. Cancer Res 1987; 47: 3005–3011.
Wheatley K, Hills RK, Burnett AK . Problems with up-front randomization in clinical trials. J Clin Oncol 2006; 24: 5471–5472.
The author declares no conflict of interest.
Rights and permissions
About this article
Cite this article
Schiffer, C. Commentary on: ‘Age, not therapy intensity, determines outcomes of adults with acute myeloid leukemia’. Leukemia 30, 1636–1637 (2016). https://doi.org/10.1038/leu.2016.141